Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NICE
Pharma
England's NICE not sold on Lilly's Kisunla despite UK approval
Lilly's Alzheimer's treatment fell to the same fate as rival Leqembi in the U.K., with the region's cost watchdog deeming the med not cost-effective.
Zoey Becker
Oct 23, 2024 11:00am
NHS England proposes phased rollout for Lilly's obesity med
Oct 3, 2024 3:22pm
Eisai, Biogen's Leqembi nabs UK nod but not reimbursement
Aug 22, 2024 9:23am
NICE signs off on Vertex, CRISPR's Casgevy for beta thalassemia
Aug 7, 2024 8:20pm
AZ, Daiichi's Enhertu turned away by NICE on pricing grounds
Jul 29, 2024 9:16am
Regulatory tracker: CSL's gene therapy secures new coverage
Jun 28, 2024 9:30am
